"
Team:Calgary/Project/Collaboration/ParisBettencourt
From 2013.igem.org
| Line 9: | Line 9: | ||
<p>Biosensors are a common theme in iGEM and synthetic biology. In the six years of iGEM there have been XXX biosensors most of which are XXX sensors. However there are not many DNA biosensors in the registry. This year team Calgary developed an E. coli biosensor and Paris Bettencourt is developing a M. tuberculosis sensor. Both the teams are using relatively new technology to create these sensors, namely, Transcription Activator Like Effector (TALE) and Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR). </p> | <p>Biosensors are a common theme in iGEM and synthetic biology. In the six years of iGEM there have been XXX biosensors most of which are XXX sensors. However there are not many DNA biosensors in the registry. This year team Calgary developed an E. coli biosensor and Paris Bettencourt is developing a M. tuberculosis sensor. Both the teams are using relatively new technology to create these sensors, namely, Transcription Activator Like Effector (TALE) and Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR). </p> | ||
| - | <p>TALEs are modular in nature and they contain domains called <b>repeat variable domains (RVD)</b> which are 34 amino acid repeats with and amino acid number 12 and 13 are variable which determines which nucleotide the | + | <p>TALEs are modular in nature and they contain domains called <b>repeat variable domains (RVD)</b> which are 34 amino acid repeats with and amino acid number 12 and 13 are variable which determines which nucleotide the TALE binds to.</p> |
<p>One of the binding elements of both these projects is the modular nature of both the TALEs and CRISPRs. These elements can be customized to detect any DNA of interest we desire. Therefore, we can use both of these systems to detect pathogenic <i>E. coli </i> or <i>M. tuberculosis</i>. However, the striking differences between the systems are how the teams are using these systems. Calgary is developing an in vitro biosensor that can be used by people in the field and Paris-Bettencourt is developing an in vivo biosensor that is used as a diagnostic tool in a laboratory environment. </p> | <p>One of the binding elements of both these projects is the modular nature of both the TALEs and CRISPRs. These elements can be customized to detect any DNA of interest we desire. Therefore, we can use both of these systems to detect pathogenic <i>E. coli </i> or <i>M. tuberculosis</i>. However, the striking differences between the systems are how the teams are using these systems. Calgary is developing an in vitro biosensor that can be used by people in the field and Paris-Bettencourt is developing an in vivo biosensor that is used as a diagnostic tool in a laboratory environment. </p> | ||
Revision as of 22:41, 24 September 2013
Paris Bettencourt
Paris Bettencourt
Biosensors are a common theme in iGEM and synthetic biology. In the six years of iGEM there have been XXX biosensors most of which are XXX sensors. However there are not many DNA biosensors in the registry. This year team Calgary developed an E. coli biosensor and Paris Bettencourt is developing a M. tuberculosis sensor. Both the teams are using relatively new technology to create these sensors, namely, Transcription Activator Like Effector (TALE) and Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR).
TALEs are modular in nature and they contain domains called repeat variable domains (RVD) which are 34 amino acid repeats with and amino acid number 12 and 13 are variable which determines which nucleotide the TALE binds to.
One of the binding elements of both these projects is the modular nature of both the TALEs and CRISPRs. These elements can be customized to detect any DNA of interest we desire. Therefore, we can use both of these systems to detect pathogenic E. coli or M. tuberculosis. However, the striking differences between the systems are how the teams are using these systems. Calgary is developing an in vitro biosensor that can be used by people in the field and Paris-Bettencourt is developing an in vivo biosensor that is used as a diagnostic tool in a laboratory environment.
TALK ABOUT HOW YOU GUYS MET IN EUROPE AND IT WAS LOVE AT FIRST SIGHT OR SOMETHING LIKE THAT.
To begin our collaboration both the teams reviewed biosensors that are already in the registry and has been part of iGEM thus far. Both the teams had a video conferences weekly to think about basic questions regarding our project such as what is a biosensor? What are the elements of a biosensor? What are some of the biosensors that are already in the registry? What type of biosensors are they? Inputs and outputs? How have the registry biosensors evolved over the years? Where do our projects fit in in the grand scheme of the biosensors? What are some of our strengths (for both projects) and weaknesses (both projects)? WE NEED TO ANSWER ALL THESE QUESTIONS AND THE STATS WILL FIT IN NICELY I THINK.
JUSTIFY WHY WE DECIDED TO BUILD EACH OTHER A LOVELY TALE AND A LOVELY CRISPR. AND LINK TO THE PLANNED PARTS. Also list some characterization idea/ studies we might do as a future direction
